Human Insulin Market to Grow to be Valued USD 43.33 Billion by 2025
Growing diabetic
population to drive global human insulin market during forecast period
According to TechSci Research report, “Global Human
Insulin Market
By Indication (Type I Diabetes, Type II
Diabetes), By Brand (Lantus, Humulin R, Novolin R, Humulin N, Exubera,
Afrezza, Novolin N), By Route of Administration (Subcutaneous, Transdermal,
Nasal, Intravenous, Oral and Others), By Type
(Basal, Bolus, Pre-mixed, Biosimilar, Traditional), By Onset Time (Rapid acting, Short-acting,
Intermediate acting, Long acting, Pre-Mixed, Inhaled, Ultra-long Acting),
By Products (Insulin Pens, Insulin Pumps,
Infusion System, Injections), By Region, Forecast & Opportunities,
2025”, Global human insulin market was valued
at USD 26.91 Billion in 2019 is expected to grow at a steady CAGR of 8.01%
during the forecast period. Growing geriatric population, growing
global diabetic population, rising prevalence of obesity, and increasing demand
for human insulin analogs are contributing to the growing demand for human
insulin to control the blood sugar levels in the body. Diabetes is a chronic
disorder which further makes the body prone to many more diseases, thus it is
quite important to handle the glucose levels of the body in an efficient way.
In the past few years, diabetes has not only been limited to the geriatric population,
but young population is equally prone to diabetes. Technology advancements and
urbanization have resulted in reduced physical activities which are required
for a healthy body. This kind of unhealthy lifestyle makes people prone to
obesity, diabetes and many other chronic diseases; consequently, driving the
human insulin market, globally. However, the complexity and the expensiveness
of the product might restrain the market as every diabetic patient might not be
able to afford human insulin and hence, shifts to conventional medicines.
Browse 227 Figures spread
through 311 Pages and an in-depth TOC on " Global
Human Insulin Market"
https://www.techsciresearch.com/report/human-insulin-market/4637.html
The
global human insulin market is segmented on the basis of indication, brand, route
of administration, type, onset type, products and region. Based on indication,
global human insulin market can be segregated into type I diabetes and type II
diabetes. Type I diabetes is leading the market as all the patients suffering
from Type I insulins are
consuming human insulin as the primary method of treatment.
Some of the leading players in global human
insulin market include Nektar Therapeutics, MannKind Corporation, Novo Nordisk
A/S, Torrent Pharmaceuticals, Inc., Eli Lilly and Company, A-S Medication
Solutions, RemedyRepack Inc., Sedico Co., Pharmaceutical Company, Sanofi S.A.,
Gan & Lee Pharmaceuticals, BioGenomics Ltd., Pfizer Inc., PerkinElmer,
Merck & Co., Inc, Biocon Limited, Wockhardt Ltd., Ypsomed AG, Becton
Dickinson and Company, B. Braun Melsungen AG, Baxter International Inc., etc. In
order to expand their market share, the companies adopt various strategies including
organic and inorganic like mergers & acquisition. For instance, Eli Lilly
and Boehringer Ingelheim GmbH, the two renowned biotech & pharma companies in
the healthcare sector have joined hands to develop Basaglar (Insulin Glargine) for
better and advanced treatment of diabetic patients.
Download
Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=4637
Customers
can also request for 10% free customization on this report.
“In
terms of regional analysis, North America dominated the global human insulin
market in 2019 due to increasing cases of diabetes in countries like United
States and Canada. However, Asia-Pacific region is expected the fastest growing
region as it comprises of countries like China and India which have high
prediabetic and diabetic population. Additionally, rising awareness pertaining
to the use of human insulin in diabetes and strong distribution network of
leading product manufacturers is anticipated to positively impact the growth of
the market in the region.” said Mr. Karan Chechi, Research Director with
TechSci Research, a research based global management consulting firm.
“Global Human Insulin Market By
Indication (Type I Diabetes, Type II
Diabetes), By Brand (Lantus, Humulin R, Novolin R, Humulin N, Exubera,
Afrezza, Novolin N), By Route of Administration (Subcutaneous, Transdermal,
Nasal, Intravenous, Oral and Others), By Type
(Basal, Bolus, Pre-mixed, Biosimilar, Traditional), By Onset Time (Rapid acting, Short-acting,
Intermediate
acting, Long acting, Pre-Mixed, Inhaled, Ultra-long Acting), By Products (Insulin Pens, Insulin Pumps, Infusion System, Injections), By
Region, Forecast & Opportunities, 2025”, has
evaluated the future growth potential of global human insulin market and
provided statistics & information on market size, shares, structure and
future market growth. The report intends to provide cutting-edge market
intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges and opportunities in global human insulin market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]